An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Albert Qin; Raymond W Urbanski; Lennex Yu; Tasfia Ahmed; John Mascarenhas

doi:10.3389/fonc.2023.1109866

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Front Oncol. 2023 Jan 19:13:1109866. doi: 10.3389/fonc.2023.1109866. eCollection 2023.

Authors

Albert Qin¹, Raymond W Urbanski², Lennex Yu¹, Tasfia Ahmed², John Mascarenhas³

Affiliations

¹ PharmaEssentia Corporation, Taipei, Taiwan.
² PharmaEssentia USA Corporation, Burlington, MA, United States.
³ Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Abstract

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes.

Keywords: alternative dosing strategy; clinical study; interferon; myeloproliferative neoplasm; pegylated interferon; polycythemia vera; ropeginterferon alfa-2b.